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THE effects of injection of the four nucleotides obtained from ribonucleic
acid on the tissues of normal and tumour-bearing mice have been described
(Barakan, Barker, Gulland and Parsons, 1948; Parsons, Gulland and Barker,
1947). Further experiments have now been carried out to note the action
of purine and pyrimidine bases on sarcoma growth, and to correlate if possible
the biological activities of the compounds with their chemical structure. These
experiments fall into two groups:
(a) Those relating to the amino and hydroxy purines,
(b) those relating to uracil and its derivatives.
Both pure-line and stock mice were grafted with homologous or heterologous
sarcomas, including C57 and S37 and the Crocker sarcoma, the latter known
to be very refractory to inhibitory action (Badger, Elson, Haddow, Hewett
and Robinsoir, 1942). The technique for treatment of the grafted mice was
similar to that previously described, but the standard dose (0025 g.) was reduced
in proportion to the toxicity of any particular compound, or where the condition
of the mouse necessitated this. Insoluble or relatively insoluble compounds
such as xanthine, guanine, adenine or hypoxanthine were administered as fine
suspensions in the same media as used for the soluble compounds. Examination
of the tissues at varying intervals showed that all compounds injected as sus-
pensions were rapidly removed within 24 hours with the exception of guanine,
the relative inactivity of which on tumour growth seems to be due to its marked
insolubility. Deposits of the injected guanine were found at the site ofinjection
long after the last dose. Table I summarizes the results obtained. The total
number of control mice was in all cases the same as the total number of treated
mice.
The amino and hydroxy purines.
It had been noted that adenylic acid or adenosine produced shock when
injected into mice, and it seems probable that this effect was due to the adenine
radical, of which the pyrimidine ring is in a lower state of oxidation than those
of the other compounds used which do not induce shock. Injection of adenine
in doses comparable with those used for adenosine or adenylic acid has been
found to cause immediate and profound shockwith heavymortality, the minimum
sublethal dose being 0005 g. On the other hand, hypoxanthine injected in
average doses of 0015 g. produced no shock. It is seen from Table I that this
purine markedly inhibits sarcoma growth. Toxic symptoms appear on repeated
dosage with considerable mortality.
These experiments suggest that the property of inducing shock shown by
adenylic acid is dependent on neither the phosphoryl nor the carbohydrateG. R. BARKER, M. M. DHAR AND L. D. PARSONS
radical, but may be connected with the presence of the amino group in position
6 in the adenine radical.
Xanthine injected in tumour-bearing mice was removed from the tissues
in 24 hours, but no inhibition of sarcoma growth was observed. Injected into
normal mice in doses of from 0-02-0*025 g. 5 times weekly, xanthine induces,
after the first or second treatment, a moderate eosinophilia which is also
characteristic of guanylic acid. It is interesting to note that uridylic acid,
which, like xanthine, contains the dihydroxypyrimidine ring system, also
induces a moderate eosinophilia in normal mice. It would therefore seem that




Total Total Nof weight of weight of Ratio Compound used. of mtce treated control T./C. treated. tumours tumours
(g.). (g.).
Adenine sulphate . . . . 7 . 119 . 19-4 . 0614
Adenine . . . . . 10 . 13-1 . 242 . 0 542
Adenosine . . . . . 6 . 9 7 . 147 . 066
Guanine hydrochloride . . . 14 . 26-6 35- 9 . O741
Guanine . . . . 6 . 13-9 . 15-5 . 0-897
Guanosine . . . . . 5 . 4.5 . 10-0 . 0-45
Hypoxanthine . . . . 18 . 17-1 . 35 1 . 0-488
Xanthine . . . . . 15 . 73-2 . 75-0 . 0-964
Uracil. . . . . . 18 . 80*4 . 66-3 . 1-21
4-aminouracil . . . . 61 . 65-8 . 139-8 . 0-471
4-methyl-uracil . . . . 40 . 96-4 . 85- 7 . 1-13
Orotic acid . . . . . 17 . 38-4 . 39'4 . 0 975
4:5-diamino-uracil . . . 8 . 21-1 . 25-7 . 0-82 4-amino-5-methyl-uracil . . 30 . 76-1 . 66-2 . 1- 15
4-amino-uracil with guanylic acid . 11 . 19.0 . 28-1 . 0-676
Uracil and related compounds.
Previous work (Barakan et al., 1948) has shown that uracil, uridine or uridylic acid behave differently to the purine compounds in their effect on
tumour growth, and exert a stimulatory action on the development of mouse
sarcoma. This difference in behaviour may be due to the different ways in
which the injected compounds are metabolized. It is known (Brown, Peter-
mann and Furst, 1948; Getler, Roll, Tinker and Brown, 1949; Arvidson, Eliasson, Hammarsten, Reichard, von Ubisch and Bergstrom, 1949) that,
whereas ingested adenine is utilized in the synthesis of pentose nucleic acid,
uracil is not, and that orotic acid is probably a precursor of uridine and cytidine.
Furthermore, neither xanthine nor hypoxanthine are utilized in polynucleotide
synthesis. It therefore seemed desirable to investigate further the biological
effects consequent on substituting various groups in the uracil molecule, and a
number of compounds were accordingly synthetized, including orotic acid and
other derivatives, which might act as purine precursors.
As seen from TableI, orotic acid has no observable action on tumour growth.
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4:5-diamino-uracil administered in the form of a salt, or as the freshly-prepared
base, exhibited high toxicity, and treatment was discontinued after a few doses.
4-aminouracil, when injected in aqueous solution in stock and pure line mice,
produced considerable inhibition of the grafted tumour, statistical analysis
showing that the differences in tumour weights for treated and control mice
were significant. Of the tumours employed, the Crocker showed the- greatest
inhibition, whereas this sarcoma was very slightly affected by adenylic or
guanylic acid.
The possibility that the inhibitory action of 4-aminouracil may be due to
the utilization of this compound in some synthetic process in cell metabolism
leading to the formation of a purine demands further investigation. In this
connection it is significant-that 4-methyl uracil and 4-amino-5-methyl uracil,
in which purine synthesis is blocked by the methyl group, have been found to
have no inhibitory action on sarcoma growth, and-the marked difference in the
actions of 4-amino-uracil and uracil itself on tumour development is worthy
of emphasis. This difference in behaviour of these compounds is further shown
by the fact that inhibition of tumour growth was noted when guanylic acid
and 4-aminouracil were injected together in grafted mice, whereas it had been
previously observed that guanylic and uridylic acids were mutually antagonistic,
and that their respective inhibitory and acceleratory actions were cancelled out
when injected simultaneously.
Experiments are in progress to exramine other aspects of the relationship
of purine and pyrimidine compounds to sarcoma growth.
SIUMMARY.
Previous observations regarding the effects of nucleotides and related com-
pounds on the tissues of normal and tumour-bearing mice have been extended.
Adenine is found to be highly toxic, but hypoxanthine, whilst inhibiting sarcoma
growth, is toxic only on continued dosage. Xanthine has no effect on sarcoma
growth, but, like guanylic acid, produces eosinophilia; Of the three pyrimidine
bases investigated, orotic acid showed no action on tumour growth; 4:5-:di-
aminouracil was too toxic to allow of continued dosage; 4-aminouracil showed
a significant inhibiting effect on grafted tumours, the greatest effect being
observed with the Crocker sarcoma.
We are grateful to the British Empire Cancer Campaign for grants defraying
the cost of these investigations.
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